Role of natural secondary metabolites as HIF-1 inhibitors in cancer therapy

IF 2.6 4区医学 Q3 CHEMISTRY, MEDICINAL

Medicinal Chemistry Research Pub Date : 2024-05-02 DOI:10.1007/s00044-024-03219-x

Prem Shankar Mishra, Rakhi Mishra, Vaishali Manikrao Patil, Samiksha Dewangan

{"title":"Role of natural secondary metabolites as HIF-1 inhibitors in cancer therapy","authors":"Prem Shankar Mishra, Rakhi Mishra, Vaishali Manikrao Patil, Samiksha Dewangan","doi":"10.1007/s00044-024-03219-x","DOIUrl":null,"url":null,"abstract":"<div><p>Hypoxia-inducible Factor 1 (HIF-1) is a transcriptional activator that intervenes in versatile reactions to hypoxia. Natural drugs, widely distributed in plants, comprise many metabolites, possessing their potential as anti-cancer agents. Studies have highlighted HIF-1 as a potential pharmacological target for cancer therapy. Secondary metabolites derived from natural products (plant-derived or marine organisms) with unique chemical structures have demonstrated HIF-1 inhibition. Ganetespib, topotecan, PX-478, aminoflavone, fluorine-19-fluoroded xyglucose, etc. have entered clinical phases of evaluation for different types of cancer. The present work describes role of HIF-1 in tumor progression, summarizes plant based inhibitors such as berberine, rohitukine, harringtonine, acronycin, nuciferine, evodiamine, matrine, etc. Some of the major categories with HIF-1 inhibitory potential are alkaloids, flavonoids, steroids, etc. The manuscript aims to benefit the discovery and development of anti-cancer therapeutics from natural compounds.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"33 5","pages":"721 - 734"},"PeriodicalIF":2.6000,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Chemistry Research","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00044-024-03219-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Hypoxia-inducible Factor 1 (HIF-1) is a transcriptional activator that intervenes in versatile reactions to hypoxia. Natural drugs, widely distributed in plants, comprise many metabolites, possessing their potential as anti-cancer agents. Studies have highlighted HIF-1 as a potential pharmacological target for cancer therapy. Secondary metabolites derived from natural products (plant-derived or marine organisms) with unique chemical structures have demonstrated HIF-1 inhibition. Ganetespib, topotecan, PX-478, aminoflavone, fluorine-19-fluoroded xyglucose, etc. have entered clinical phases of evaluation for different types of cancer. The present work describes role of HIF-1 in tumor progression, summarizes plant based inhibitors such as berberine, rohitukine, harringtonine, acronycin, nuciferine, evodiamine, matrine, etc. Some of the major categories with HIF-1 inhibitory potential are alkaloids, flavonoids, steroids, etc. The manuscript aims to benefit the discovery and development of anti-cancer therapeutics from natural compounds.

Abstract Image

查看原文本刊更多论文

天然次生代谢物作为 HIF-1 抑制剂在癌症治疗中的作用

缺氧诱导因子 1（HIF-1）是一种转录激活因子，可干预多种缺氧反应。天然药物广泛分布于植物中，由许多代谢产物组成，具有抗癌潜力。研究表明，HIF-1 是治疗癌症的潜在药理靶点。从天然产品（植物或海洋生物）中提取的次生代谢物具有独特的化学结构，可抑制 HIF-1。Ganetespib、topotecan、PX-478、氨基黄酮、氟-19-氟代木糖等药物已进入临床评估阶段，用于不同类型的癌症。本研究阐述了 HIF-1 在肿瘤进展中的作用，总结了小檗碱、罗布麻碱、哈灵通碱、阿创霉素、核苷酸、依伏二胺、马替林等植物抑制剂。具有 HIF-1 抑制潜力的主要类别包括生物碱、黄酮类、类固醇等。该手稿旨在促进从天然化合物中发现和开发抗癌疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicinal Chemistry Research 医学-医药化学

CiteScore

4.70

自引率

3.80%

发文量

162

审稿时长

5.0 months

期刊介绍： Medicinal Chemistry Research (MCRE) publishes papers on a wide range of topics, favoring research with significant, new, and up-to-date information. Although the journal has a demanding peer review process, MCRE still boasts rapid publication, due in part, to the length of the submissions. The journal publishes significant research on various topics, many of which emphasize the structure-activity relationships of molecular biology.